mentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/ UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1 . However, it should be stressed that evidence-based studies for follow-up are largely missing. 
Introduction
The documentation of patients with neuroendocrine neoplasms (NEN) should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. The documentation should be both simple but nevertheless as complete as possible and should include basic demographic details to identify a specific patient, family history, tumor histology and biology, course of the disease, tumor board evaluations, diagnostic tests, and therapeutic interventions. Additional data about biological samples, such as tumor specimens preserved in paraffin-embedded or fresh frozen samples and the patient's samples like blood or serum, would be of high interest for current and future translational research. This information is essential for treatment and follow-up strategies adjusted to the specific features of the tumor of the patient. Furthermore, standardized documentation acts as a key precondition to learn more about patients with specific tumor subtypes and regarding the impact of treatment modalities on the course of the disease. In the present clinical setting, the timing of data collection and content of documented data vary considerably. Therefore, comparison of data from different centers is frequently hampered by lack of data uniformity.
During the ENETS Standards of Care Conference Advisory Board meeting organized in Antibes, France in 2015, a group of physicians with extensive experience in the clinical care of patients with gastroenteropancreatic (GEP), bronchopulmonary (BP) and thymic NEN met to write recommendations on the unified collection of data and suggested time intervals for follow-up investigations. These guidelines recognize the diversity of tumor subtypes, the actual WHO and TNM classifications, the individual clinical course of the disease as well as the resource implications relevant to the growing costs of the European health care systems. Particular attention was paid to recommend only those investigations that would have a significant impact on further therapeutic strategies.
It is advocated that follow-up occurs in specialized NEN centers or at least in hospitals with close collaboration with specialized NEN centers. It is of minor importance which specialty (e.g., oncology, gastroenterology, endocrinology, pulmonology or surgery) follows the patient as long as experienced NEN specialists are present. Regularly NEN tumor boards with expert panels are essential for follow-up. Besides all new patients, patients with recurrence or progression as well as patients with other relevant problems during follow-up should be presented at the multidisciplinary tumor board.
Documentation at Follow-Up Should Adhere to the Present WHO Classification and Recognize the ENETS Consensus Guidelines and Recommendations for TNM Staging
The panel agreed that the following categories best define the different tumor entities observed in the clinical setting. The categories follow the WHO 2010 classification [1] as well as the ENETS consensus guidelines from 2011 [2] and 2016 [3] and the recommendations for TNM staging [4, 5] in order to better compare data from different centers. We are aware that a revised WHO classification will be published within the next few years, also considering G3 neuroendocrine carcinomas (NEC G3, poorly differentiated) versus G3 neuroendocrine tumors (NET G3, well differentiated) as different entities based upon differentiation. This may refine the current classifications, if an objective definition of differentiation is achieved. This subclassification may have an impact on treatment, but may not change the general follow-up procedures and recommendations. It should be stressed that evidence-based studies for follow-up are largely missing.
In this article, we have revised the previous recommendations [6] and introduced a new set-up, which we find easier to apply on the daily routine for follow-up on patients with GEP, BP and thymic NEN ( Table 1 ) . For BP NEN, typical and atypical carcinoids as well as large-cell neuroendocrine carcinomas have been included as per ENETS guidelines [7] and Danish guidelines [8] . Smallcell lung cancer is not included in the article as it is beyond the scope of these recommendations and as it is dealt with in several other guidelines. We have included a suggested follow-up regime for thymic NEN, although evidence for follow-up in these tumor types is lacking.
Firstly, the different NEN are divided according to the organ of the primary tumor, including cancer of unknown primary. Secondly, the tumors are recorded according to their grading (GEP NEN), differentiation (thymic and BP NEN), status, and operative outcome, respectively ( Table 1 ) . Data on stage (TNM -including size of the primary but also tumor burden), tumor aggressiveness (stable vs. progressive disease), functionality, chromogranin A (CgA) levels, and hereditary disease, which all may have an impact and thus may affect the follow-up Table 1 , but are mentioned in Table 2 .
Functioning tumors (the specific secreted hormone being their tumor marker) should be followed up with hormone analyses and imaging every 3-12 months depending on hormone-related symptoms and tumor aggressiveness. If recurrence or persistence is highly suspected, functional tests, for example fasting test for insulinomas and secretin test for gastrinomas, may be required.
Recommendations for Follow-Up Investigations
It is recommended that follow-up should be performed in specialized NEN centers to obtain specific biochemistry and high-quality imaging. If relevant from the above, the patient documentation should be presented at the multidisciplinary tumor board for further planning. 
General Recommendations

General Comments
Tumor-specific follow-up investigations are mainly based on clinical symptoms, imaging procedures such as functional and cross-sectional imaging, and tumor markers. However, an expert physician who is in charge of an individual patient is able to judge the patient's general health and even prognosis by a careful history and examination, assessment of weight loss, muscular mass and symptoms, for example heart function in cases of the carcinoid syndrome and possible carcinoid cardiac disease. However, these items are difficult to compare inter-and intraindividually and should be supported where possible by "objective" procedures such as imaging methods and serum/plasma tumor markers.
Tumor Markers
Chromogranin A At present, the most common and reliable tumor marker is plasma CgA for patients with G1 and G2 NEN. However, plasma CgA is generally normal in patients with nonfunctioning duodenal NEN, appendiceal NEN, small rectal NEN and insulinomas and is often normal in patients with localized G1 and G2 NEN and in patients with G3 NEN (some G3 NET can have increased CgA plasma levels). Plasma CgA may reflect tumor mass and changes in tumor burden but also secretory activity of the tumor [9] [10] [11] [12] [13] . In addition, plasma CgA may be an indicator for prognosis mainly in small intestinal NEN [9, 11, 14] . Furthermore, an increase in the CgA level has been suggested as the first indicator of recurrence [15] . However, fluctuations in plasma CgA are frequently seen and in case of more than 25% increase from the previous level, determination of CgA should be repeated. If still increased, imaging with CT/MRI or SRI is recommended. Plasma CgA may also be elevated without the presence of NEN, for example due to the use of proton pump inhibitors, chronic atrophic gastritis, or decreased kidney and liver function [16, 17] .
In some clinical trials with new targeted agents, significant reductions in CgA have been associated with better outcomes [14] . However, variations in plasma CgA without changes in imaging or symptoms compared to baseline levels should not be considered for treatment modification. Since several assay kits exist, but with no international standard, caution is recommended when comparing values from kits of different manufacturers [10] . Furthermore, each CgA kit has to be evaluated concerning sensitivity and specificity. CgA levels and normal ranges differ in the literature and from laboratory to laboratory and from assay to assay because they are measured by different methods. Therefore, "cutoff levels" recommended for decision-making should be applied with caution, and each institution has to define its own "cutoff levels." Chromogranin B Plasma chromogranin B (CgB) may be of value in the follow-up of BP and rectal NEN [18] . However, the availability for CgB is limited.
Neuron-Specific Enolase Plasma neuron-specific enolase may act as an additional marker in patients with G3 NEN [19] and has been shown to be a prognostic marker in GEP NEN [14, 20] .
5-Hydroxyindoleacetic Acid
Twenty-four-hour urine 5-hydroxyindoleacetic acid (5-HIAA) is an established marker for patients with serotonin-producing small intestinal/appendiceal and BP NEN, in particular in the presence of the "carcinoid syndrome." However, the sensitivity is less than that of plasma CgA [21] . Recently, analyses for serum 5-HIAA have been introduced [22] . Urine 5-HIAA is influenced by a number of dietary factors, for example avocado, banana, tomato and others, and by drugs such as coumarin, paracetamol, phenacetin, aspirin and others. Serotonin Measurement of serum serotonin is not recommended for follow-up [23] .
Gastrointestinal Hormones
In patients with functioning pancreaticoduodenal tumors (insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma, etc.), the respective hormones are used as diagnostic markers. However, the prognostic value of change in hormone values is uncertain.
NT-pro-Brain Natriuretic Peptide Measurement of NT-pro-brain natriuretic peptide (NT-pro-BNP) once yearly or at least every 2nd year is recommended in the follow-up of patients with carcinoid syndrome to reveal development and to control carcinoid heart disease [24] . It is supplemented by echocardiography or eventually MRI of the heart [25] [26] [27] .
Imaging
For G1 and G2 neuroendocrine tumors, which are generally slow growing, follow-up imaging is usually between 6 and 12 months but some patients may require imaging evaluation earlier. Cross-Sectional Imaging Current imaging procedures encompass CT, MRI, abdominal ultrasound (US), with or without contrast enhancement, and SRI. Primarily CT is used because of its standardized imaging planes that facilitate comparison between examinations and since the tissue resolution is better in cases of extended tumor load. Additionally, MRI may be preferable in younger patients having several imaging procedures, to reduce radiation dose. In addition, MRI is superior to CT to evaluate liver metastases, pancreatic and rectal NEN. Abdominal US may, however, be used for follow-up if documentation allows one to compare findings obtained during different follow-up visits. US is also valuable for the occasional patients in whom liver metastases are better visualized by US than by CT and for biopsy of new or rapidly growing lesions.
Thoracoabdominal CT, including three-phase examination of the liver, is the preferred imaging for follow-up as it is widely available and has relatively low cost. However, in many centers, abdominal MRI is preferred and if resection of liver metastases is considered during followup, it is generally recommended to perform MRI to reveal small liver metastases not visualized by CT [28] .
Functional Imaging Somatostatin receptor scintigraphy (SRS) with
111 Inpentetreotide (octreotide scintigraphy), including planar imaging and SPECT, has been the mainstay for SRI although most NEN centers currently perform PET-CT with 68 Ga-DOTA-conjugated peptide (e.g., TOC/NOC/ TATE) as this PET imaging technique is superior to SRS showing higher sensitivity, spatial resolution, identification of more lesions, less radiation, and a shorter investigation time [29] [30] [31] [32] and is therefore preferred in followup. Other PET tracers, such as 64 Cu-DOTATATE-PET-CT [30, 31] , 18 In-DTPA-exendin-4 SPECT-CT [37] , may be used in follow-up if positive at baseline and if available at the center. Currently, there are only limited data available of PET-based imaging for routine follow-up, and its significance in this respect is currently not possible to define. However, PET may reveal metastases not seen on SRS or CT, particularly in bone and lymph nodes [30, 31, [33] [34] [35] . Grade uptake at SRI as well as homogeneity of uptake should be specified [38] , also to evaluate the eligibility for peptide receptor radionuclide treatment. 18 FDG-PET-CT has a higher sensitivity than SRS in patients with G3 NEN and should instead be utilized for follow-up in this group of patients [39] . Furthermore, 18 FDG-PET-CT is frequently positive in G2 NEN with a high Ki-67 index and in aggressive and rapidly growing NEN [39, 40] . In addition, 18 FDG-PET is an important prognostic factor in NEN, as patients with a positive PET have a significantly poorer prognosis than patients with a negative one [39, 41] . Additionally, evidence of different uptake in 18 FDG-PET and SRI in the same patient reflects the tumor heterogeneity and could have an impact in decision-making criteria [42] . However, 18 FDG-PET-CT is not commonly used for follow-up and in general only when SRI is negative, in patients with G3 NEN or in other selected subgroups of patients.
Endoscopy
Upper endoscopy should be utilized in the follow-up and control of gastric NEN and colonoscopy and sigmoidoscopy should be used for the follow-up of patients with colorectal NEN. National follow-up strategies should be followed to early diagnose metachronously appearing secondary gastrointestinal malignancy. Follow-up bronchoscopy for recurrence is indicated in patients with BP neuroendocrine tumors localized preoperatively by bronchoscopy.
Endoscopic ultrasonography, eventually with biopsy, of the stomach, duodenum, pancreas, and rectum could be useful for follow-up in selected patients (T and N staging) and also in patients with MEN-1. Capsule endoscopy (jejunum/ileum) is rarely indicated in the follow-up. Endoscopic bronchial ultrasonography may be indicated in follow-up if biopsy of pathologic peribronchial lymph nodes is required.
Histopathology
In patients with tumor or metastatic recurrence and/ or rapid or unexpected progression imaging-guided biopsy should be considered to re-evaluate the Ki-67 proliferation index. An increase may change the treatment strategy or may rule out secondary malignances. Biopsies should be taken from new or rapidly growing metastases. Echocardiography "Carcinoid heart disease" with involvement of the tricuspid and pulmonary valves is observed in up to 10-20% of patients with the carcinoid syndrome [43] . In all patients with carcinoid syndrome and in patients with G1/ G2 GEP NEN or BP NEN with high 24-h urine, 5-HIAA level echocardiography should be performed at diagnosis and thereafter annually or shorter if clinically indicated [25] [26] [27] . The measurement of NT-pro-BNP should be performed as well [24] .
Progression Rate
Progression disease rates within G1/G2 GEP NEN and BP NEN are not always well defined only using the grading system. Stable and slowly growing tumors should be differentiated from more aggressive tumors in follow-up schedules, i.e., patients with aggressive and rapidly growing tumors should have a follow-up with imaging every 3 months while patients with stable or slowly growing tumors may have imaging every 6-12 months ( Tables 1 , 2 ). Efforts to quantify the rate of progression should be performed. Furthermore, if stable disease is seen over longer time, the interval between follow-up visits and imaging may be further extended. Trying to define the progression rate and the influence in follow-up for metastatic disease, a proposed timeline for follow-up regarding tumor progression is given in Figure 1 .
Hereditary Diseases
Patients with hereditary diseases such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindaus syndrome (VHL), or neurofibromatosis type 1 should be followed according to the organ of the primary tumor, for example the pancreas and duodenum. Guidelines for the follow-up of non-GEP disease or manifestations, for example parathyroid or pituitary adenomas in MEN-1, brain and kidney manifestations in VHL and GIST in neurofibromatosis type 1, are not described in these recommendations as they are beyond the scope of this review and are dealt with in several other guidelines.
Tumor-Specific Recommendations
The recommended follow-up for NEN, including GEP NEN, BP (typical and atypical) carcinoids, large-cell neuroendocrine carcinomas as well as thymic NEN, is given in Table 1 . The panel agrees that the level of evidence for follow-up recommendations is low. The recommendations are in accordance with those given in the WHO 2010 classification of GEP NEN, the ENETS 2016 guidelines for GEP NEN [3] and the recent guidelines for BP NEN [7] .
Follow-up is life-long for most patients, with the exceptions mentioned in Table 1 . The comprehensive Table 1 on follow-up is based on the organ of the primary tumor and is intended to give a simple overview or catalog for the clinician. Therefore, some of the schemes are repeated from one organ to the other. The panel did not distinguish in the follow-up between patients with G1 and G2 GEP NEN, whereas patients with G3 GEP NEN were considered as a separate group.
In general, follow-up for resected or nonresected tumors are placed in the same group, but the intervals between follow-ups are in general shorter in patients with residual tumor or metastases compared to patients with curatively resected tumor or metastases as well as in patients with aggressive disease ( Table 2 ) . The follow-up investigations that should be documented to visualize the specific course of the disease in an individual patient are summarized in Tables 1 and 2 and in Figure 1 .
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